





IN THE CLAIMS


1-39. (canceled)



40. (currently amended) A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the group of compounds with structures listed below:











































































41-54. (canceled)